10x Genomics Inc. announced a series of product updates that will be presented at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Fla. The latest developments across 10x Genomics' leading Chromium and Visium platforms and the highly anticipated Xenium launch expected later this year showcase the company's leadership and innovation at the forefront of single-cell analysis, spatial biology, and in situ technology. As part of the company's robust R&D pipeline, 10x Genomics is driving innovation to enable broad adoption of the Chromium single-cell platform by increasing access to more sample types, removing bottlenecks, and giving researchers a more flexible and streamlined workflow.

10x Genomics announced the compatibility of its recently launched Fixed RNA Profiling Kit to enable single-cell transcriptomics on dissociated formalin-fixed, paraffin-embedded (FFPE) tissues. This capability enables single-cell analysis on preserved biobank samples for the first time ever. FFPE tissues are ideal for translational and clinical research, yet have remained inaccessible for single-cell analysis until now.

Both the Fixed RNA Profiling Kit and the previously announced Nuclei Isolation Kit 10x Genomics' first sample preparation product, are now shipping. 10x Genomics announced the launch and pre-order availability of two new products in its Visium portfolio, the leading spatial discovery platform: Visium CytAssist - The company's first spatial instrument, Visium CytAssist helps researchers bridge the world of histology and genomics and enables spatial profiling insights to be gained from an expanded range of FFPE samples. The compact, benchtop system simplifies sample processing by facilitating the transfer of analytes from tissue sections pre-mounted on standard glass slides to Visium slides.

Visium for FFPE v2: Demonstrating its continued commitment to innovation and rapid advancements, 10x Genomics is launching the second version of its spatial FFPE workflow, less than one year after releasing the initial Visium for FFPE assay. Visium for FFPE v2 features several product advancements and workflow improvements, including the flexibility for larger capture areas and the ability to profile RNA and dozens of proteins simultaneously in the same FFPE tissue section at high spatial resolution.  The v2 assay is expected to begin shipping later this month. Building on its leadership and innovation in single-cell and spatial analysis, 10x Genomics is planning to launch its Xenium platform for in situ analysis later this year.

At launch, Xenium is expected to offer single-molecule RNA analysis at subcellular resolution and be compatible with both fresh frozen and FFPE tissues. In addition, 10x Genomics is developing Xenium to have the high throughput of any instrument in its class.